Agenus Inc Total Liabilities
Agenus Inc total liabilities. Based on the latest financial reports, Agenus Inc (AGEN) has total liabilities worth $378.54 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Agenus Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Agenus Inc (1999–2025)
Total liabilities of Agenus Inc from 1999 to 2025. This chart illustrates how Agenus Inc's total liabilities have evolved over time, based on quarterly financial data. Explore AGEN long-term investments to assets to see how much of total assets are deployed in long-term investments.
Agenus Inc Competitors by Total Liabilities
The table below lists competitors of Agenus Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eikon Therapeutics, Inc. Common Stock
NASDAQ:EIKN
|
USA | $313.07 Million |
|
Eaton Vance Senior Floating Rate Closed Fund
NYSE:EFR
|
USA | $104.27 Million |
|
Suzhou Fushilai Pharmaceutical Co. Ltd.
SHE:301258
|
China | CN¥211.52 Million |
|
NHN KCP Corp
KQ:060250
|
Korea | ₩359.08 Billion |
|
Chengdu Rainbow Appliance Gr
SHE:003023
|
China | CN¥590.66 Million |
|
Isabella Bank Corporation
NASDAQ:ISBA
|
USA | $1.97 Billion |
|
M1 Kliniken AG
XETRA:M12
|
Germany | €56.26 Million |
|
MOZAYYX Acquisition Corp.
NYSE:MZYX
|
USA | $12.97 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Agenus Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Agenus Inc's balance sheet.
Liquidity & Leverage Metrics
Agenus Inc Total Liabilities Ratios Explained
Agenus Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Agenus Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Agenus Inc (1999–2025)
The table below shows the annual total liabilities of Agenus Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $504.66 Million | -5.26% |
| 2024-12-31 | $532.70 Million | +15.23% |
| 2023-12-31 | $462.30 Million | -1.32% |
| 2022-12-31 | $468.46 Million | +12.06% |
| 2021-12-31 | $418.05 Million | -1.87% |
| 2020-12-31 | $426.01 Million | +10.17% |
| 2019-12-31 | $386.67 Million | +24.35% |
| 2018-12-31 | $310.95 Million | +45.15% |
| 2017-12-31 | $214.22 Million | +9.23% |
| 2016-12-31 | $196.11 Million | +14.35% |
| 2015-12-31 | $171.50 Million | +232.95% |
| 2014-12-31 | $51.51 Million | +31.01% |
| 2013-12-31 | $39.32 Million | -15.80% |
| 2012-12-31 | $46.69 Million | +14.90% |
| 2011-12-31 | $40.64 Million | -10.91% |
| 2010-12-31 | $45.61 Million | -27.42% |
| 2009-12-31 | $62.85 Million | -22.28% |
| 2008-12-31 | $80.86 Million | -11.72% |
| 2007-12-31 | $91.60 Million | +1.39% |
| 2006-12-31 | $90.35 Million | +25.04% |
| 2005-12-31 | $72.25 Million | +171.47% |
| 2004-12-31 | $26.61 Million | -23.60% |
| 2003-12-31 | $34.83 Million | +208.11% |
| 2002-12-31 | $11.31 Million | -35.84% |
| 2001-12-31 | $17.62 Million | +56.46% |
| 2000-12-31 | $11.26 Million | +161.91% |
| 1999-12-31 | $4.30 Million | -- |
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvan… Read more